Pharsight

Invokamet generic

Invokamet is an antidiabetic drug, combining the active ingredients canagliflozin and metformin hydrochloride. It's owned by Janssen Pharms and was first approved for market use on August 8, 2014.

When will Invokamet generic be available?

Invokamet's generic version may be expected to hit the market after the last patent expires on July 6, 2030. This takes into account all current patents, including those resulting from a Para IV filing.

Invokamet uses

Invokamet is primarily used in the treatment of type 2 diabetes mellitus. It's effective in reducing the risk of major adverse cardiovascular events and end stage kidney disease. Additionally, it helps to prevent the doubling of serum creatinine, cardiovascular deaths, and hospitalization for heart failure in type 2 diabetes mellitus patients.

Invokamet patent expiration

Invokamet is protected by six patents, none of which has expired yet. The last patent is due to expire on July 6, 2030. Consequently, no Invokamet generic versions are expected until then. Below are the details of the patent:

EPO Oppostions filed on Invokamet

Invokamet dosage

Want to ask something?